Competition Law and Killer Acquisition Prevention Policy

A killer acquisition is generally understood as an acquisition in which an established company buys an existing, emerging, or potential competitor and the transaction has the effect—or, in the classic formulation, the purpose—of eliminating a competitive threat, including by discontinuing, delaying, redirecting, or absorbing the target’s innovation.

The issue is particularly important in digital markets, pharmaceuticals, biotechnology, artificial intelligence, medical technology, fintech, and other innovation-intensive sectors, because a start-up may exert significant future competitive pressure even when its present revenue and market share are very small.

Modern killer-acquisition prevention policy therefore focuses not only on current overlaps but also on potential competition, innovation competition, future products, nascent threats, ecosystem expansion, data advantages, and transactions falling below traditional turnover thresholds.

Below is a detailed comparative explanation. The cases are included by name and citation rather than external links, as requested.

1. Meaning of a Killer Acquisition

Traditional merger control often asks whether two established businesses compete with one another today. Killer-acquisition analysis asks an additional question:

Could the target have become an important competitive constraint in the future if it had remained independent?

A typical scenario contains:

Incumbent → innovative start-up → acquisition → loss or weakening of independent competitive development.

The target does not necessarily need to disappear completely. Competition may also be harmed where the acquiring company:

• terminates the target's project;
• reduces investment in it;
• delays commercialization;
• integrates the technology so that it ceases to constitute an independent competitive constraint;
• redirects the target away from competing with the incumbent;
• acquires important intellectual property, employees, data, or research capabilities;
• eliminates a product that could have developed into a competing platform; or
• abandons its own competing project after purchasing the target.

The last possibility is sometimes described as a reverse killer acquisition.

2. Why Traditional Merger Rules Can Miss These Transactions

One major difficulty is that merger notification systems have historically relied heavily on the parties' turnover or revenue.

A young biotechnology or technology company can have:

• almost no revenue;
• no commercially released product;
• limited market share;
• significant intellectual property;
• valuable datasets;
• advanced research;
• substantial venture investment; and
• considerable future competitive potential.

Consequently, a transaction involving a very valuable start-up might historically have escaped review because the target did not satisfy turnover thresholds.

This has encouraged jurisdictions to consider alternative mechanisms such as transaction-value thresholds, special rules for large digital firms, call-in powers and enhanced review of below-threshold acquisitions.

3. Main Objectives of Killer-Acquisition Prevention Policy

The central objective is not to prohibit large companies from purchasing start-ups generally. Acquisitions can finance innovation, provide founders with exit opportunities, combine complementary technologies and permit new products to reach customers more quickly.

Instead, competition authorities attempt to distinguish beneficial transactions from acquisitions that materially reduce competitive pressure.

A prevention framework therefore seeks to protect:

Existing competition – where the companies already compete.

Potential competition – where the target is reasonably capable of entering or expanding.

Innovation competition – where companies compete through research and product development.

Future product competition – where products have not yet reached the market.

Ecosystem competition – where a target could challenge an incumbent's wider platform or ecosystem.

4. Potential Competition Doctrine

Potential competition is one of the most important concepts in this field.

Suppose Company A controls a large digital platform. Company B is currently small but possesses technology capable of developing into an alternative platform.

If A purchases B, examining only today's market shares could understate the competitive significance of the transaction.

Authorities may therefore investigate:

• the target's technology;
• development pipeline;
• funding;
• intellectual property;
• customer growth;
• business plans;
• internal forecasts;
• entry strategy;
• technical capabilities; and
• whether other credible potential entrants exist.

The key question becomes whether the merger removes meaningful future competitive pressure.

5. Innovation Competition

Killer-acquisition policy is especially important where firms compete through innovation rather than current sales.

Imagine three companies developing competing medical technologies:

Company A: existing commercial product
Company B: product in clinical development
Company C: early-stage competing technology

Company B may have almost zero sales. Nevertheless, eliminating B could materially affect competition if B had a realistic prospect of developing a competing product.

Authorities consequently examine innovation pipelines, not merely existing products.

This principle is particularly significant in pharmaceutical and biotechnology mergers.

6. Case Law and Enforcement Examples

Case 1 – FTC v. Meta Platforms, Inc. – Instagram and WhatsApp Acquisitions

Federal Trade Commission v. Facebook, Inc. (now Meta Platforms, Inc.), U.S. District Court for the District of Columbia, No. 1:20-cv-03590.

This litigation provides one of the clearest modern examples of competition authorities examining previously completed acquisitions as part of an alleged strategy of eliminating emerging competitive threats.

The FTC's case concerns, among other conduct:

• Facebook's 2012 acquisition of Instagram; and
• Facebook's 2014 acquisition of WhatsApp.

The FTC alleges that Meta maintained monopoly power through anticompetitive conduct that included acquiring emerging competitive threats. Meta disputes the FTC's allegations. The litigation therefore illustrates how acquisitions that originally received regulatory clearance can later become central to monopolization litigation.

Importance

The case demonstrates why competition authorities increasingly examine whether a target represents a nascent competitive threat, rather than relying solely on current revenue.

It also demonstrates the potential role of retrospective scrutiny of completed acquisitions.

7. Case 2 – Illumina/GRAIL

In the Matter of Illumina, Inc. and GRAIL, Inc., FTC Docket No. 9401.

Illumina supplied next-generation DNA sequencing technology. GRAIL developed multi-cancer early-detection tests.

The FTC challenged Illumina's approximately $7.1 billion acquisition of GRAIL, arguing that Illumina could disadvantage GRAIL's rivals that depended on Illumina's sequencing technology.

In 2023, the FTC ordered divestiture. The Fifth Circuit subsequently found substantial evidence supporting the FTC's conclusion that the transaction was anticompetitive, although it vacated and remanded the FTC order because of the standard applied to part of Illumina's rebuttal evidence. Illumina then announced that it would divest GRAIL.

Importance

Although not a textbook horizontal killer acquisition, the dispute is highly important to prevention policy because it illustrates protection of future innovation competition and competition involving products still undergoing technological development.

It also became central to the debate over how authorities can review transactions involving innovative companies with little or no turnover.

8. Case 3 – Illumina/GRAIL before the Court of Justice of the European Union

Joined Cases C-611/22 P, Illumina v Commission and C-625/22 P, Grail v Commission and Illumina, Judgment of 3 September 2024.

The European aspect of Illumina/GRAIL produced an important jurisdictional ruling.

The transaction did not satisfy the ordinary EU merger thresholds because GRAIL generated no relevant turnover. The European Commission nevertheless accepted referrals under Article 22 of the EU Merger Regulation.

The Court of Justice ultimately held that the Commission could not use Article 22 in the manner adopted where the referring national authorities themselves lacked competence under their national merger-control rules to review the transaction. It therefore annulled the Commission's referral decisions.

Importance for killer-acquisition policy

This judgment demonstrates a central regulatory problem:

economically important acquisitions can fall outside turnover-based merger thresholds.

But it also demonstrates that attempts to close such enforcement gaps must remain within the jurisdiction conferred by legislation.

Therefore, modern killer-acquisition policy increasingly involves legislative notification or call-in mechanisms, rather than relying solely on expansive interpretations of existing jurisdiction.

9. Case 4 – FTC v. Meta Platforms / Within Unlimited

Federal Trade Commission v. Meta Platforms, Inc. and Within Unlimited, Inc., N.D. California; In the Matter of Meta Platforms, Inc., Mark Zuckerberg and Within Unlimited, Inc., FTC Docket No. 9411.

Meta sought to acquire Within Unlimited, developer of the VR fitness application Supernatural.

The FTC challenged the transaction, arguing that Meta was a potential entrant into the VR dedicated-fitness-app market and that acquiring Within could reduce competition and innovation.

The federal court declined to grant the FTC's requested preliminary injunction, and the administrative challenge was subsequently dismissed.

Importance

The case is significant even though the FTC did not ultimately prevent the acquisition.

It illustrates the evidentiary difficulty involved in potential-competition cases.

An authority cannot merely say:

"A large company could have entered."

It generally needs persuasive evidence concerning matters such as:

• ability to enter;
• incentives to enter;
• realistic entry plans;
• market structure;
• probable competitive effects.

Thus killer-acquisition enforcement requires evidence about the counterfactual future without the acquisition.

10. Case 5 – Adobe/Figma

European Commission Case M.11033 – Adobe/Figma.

Adobe proposed acquiring Figma, a major provider of interactive product-design software.

The European Commission opened an in-depth investigation. Its analysis examined existing competition as well as future competitive developments between the companies.

The Commission's merger analysis specifically discussed the possibility of a reverse killer acquisition—a situation where the purchaser discontinues or weakens its own competing innovation project rather than eliminating the target's project.

Adobe and Figma ultimately abandoned the transaction in December 2023.

Importance

Adobe/Figma demonstrates that modern merger control can investigate both:

Target-killing theory: purchaser eliminates the target's competing technology.

and

Reverse-killing theory: purchaser acquires the target and abandons its own competing development.

The underlying concern in either situation is the disappearance of an independent source of competitive innovation.

11. Case 6 – Dow/DuPont

European Commission Case M.7932 – Dow/DuPont (2017).

Dow and DuPont were major global agricultural-chemical companies.

The European Commission's investigation placed substantial emphasis on competition in research and development, rather than limiting the inquiry to products already sold.

The Commission concluded that the transaction raised concerns concerning innovation competition in crop protection and required substantial divestitures.

Importance

Dow/DuPont became a major reference point for innovation-theory-of-harm analysis.

It demonstrates that competition law can protect competition occurring at the R&D level even before individual research projects become commercial products.

This reasoning is closely connected with killer-acquisition prevention because many potential targets are valuable precisely because of their future innovation capabilities.

12. Case 7 – Roche/Spark Therapeutics

FTC File No. 191-0086; Roche Holdings Ltd./Spark Therapeutics, 2019.

Roche proposed acquiring Spark Therapeutics, a biotechnology company specializing in gene therapy.

The transaction received extensive antitrust examination because the parties had activities involving treatments for haemophilia.

The FTC ultimately closed its investigation without challenging the acquisition after examining whether Roche would have incentives to delay or discontinue Spark's competing developmental program.

Importance

The case illustrates an important principle:

Not every acquisition of an innovative biotechnology company by a large pharmaceutical company constitutes a killer acquisition.

Authorities must establish likely competitive harm rather than infer it simply from the target's innovative character.

The availability and strength of other pipeline competitors can be particularly important.

13. Case 8 – Nvidia/Arm

In the Matter of Nvidia Corporation/Arm Ltd., FTC File No. 211-0015 (2021–2022).

Nvidia proposed acquiring Arm from SoftBank.

Arm's processor architectures and technology were important inputs used by numerous semiconductor businesses, including firms competing with Nvidia.

The FTC challenged the acquisition, alleging that the combined company could harm competition by giving Nvidia control over technology that its rivals relied upon.

The transaction was subsequently abandoned.

Importance

Nvidia/Arm illustrates another preventive principle: authorities may intervene before competitive damage occurs where control of a strategically important technology could permit the purchaser to disadvantage present or future rivals.

This is particularly relevant to ecosystem acquisitions involving essential technological inputs.

14. Case 9 – Microsoft/Activision Blizzard

FTC v. Microsoft Corp., 2023; European Commission Case M.10646 – Microsoft/Activision Blizzard.

Microsoft's proposed acquisition of Activision Blizzard generated investigations concerning gaming ecosystems, game distribution and cloud gaming.

Different authorities reached different conclusions and remedies concerning the transaction.

The proceedings are useful for killer-acquisition policy because they demonstrate that authorities increasingly analyze how control of valuable content or technological assets can affect future markets, rather than concentrating exclusively on conventional present-day horizontal market shares.

The case also illustrates how competition authorities may reach different assessments of the same future-market evidence.

15. Policy Tool 1 – Transaction-Value Thresholds

One response to killer acquisitions is to supplement turnover thresholds with transaction-value thresholds.

The reasoning is straightforward.

Suppose:

Target revenue = €5 million

Acquisition price = €2 billion

The enormous difference between revenue and purchase price may indicate that the purchaser places significant value on:

• technology;
• intellectual property;
• users;
• data;
• personnel;
• research pipelines; or
• future competitive potential.

Germany and Austria are prominent examples of jurisdictions that introduced transaction-value-based merger notification rules.

Transaction value does not prove competitive harm. It simply helps ensure that potentially significant acquisitions can receive regulatory examination.

16. Policy Tool 2 – Mandatory Reporting by Digital Gatekeepers

Another approach is enhanced reporting requirements for particularly powerful digital platforms.

Under the EU Digital Markets Act, designated gatekeepers must provide the European Commission with information concerning certain intended concentrations involving digital-sector businesses or businesses enabling data collection.

The first gatekeepers designated by the Commission included Alphabet, Amazon, Apple, ByteDance, Meta and Microsoft.

This increases regulatory visibility into acquisitions that might otherwise escape ordinary merger notification.

Importantly, reporting and substantive prohibition are different questions: informing an authority about an acquisition does not itself establish that the acquisition violates competition law.

17. Policy Tool 3 – Call-In Powers

Another mechanism gives competition authorities authority to require notification of transactions that do not satisfy normal thresholds.

A call-in regime can be useful where a target:

• has strategically important technology;
• possesses valuable datasets;
• owns significant intellectual property;
• has rapidly expanding users;
• represents an emerging competitive threat; or
• operates in a highly concentrated innovation market.

Such mechanisms attempt to address the enforcement gap exposed by low-turnover acquisitions.

18. Policy Tool 4 – Examination of Internal Documents

Internal documents can be especially important because future competition cannot always be demonstrated through current market statistics.

Authorities may examine documents discussing:

• competitive threats;
• acquisition strategy;
• future product development;
• entry plans;
• projected growth;
• technology roadmaps;
• acquisition valuation;
• defensive reasons for purchasing a company.

The Meta litigation demonstrates the significance that authorities can place on historical acquisition documents when alleging that transactions were intended to neutralize emerging competitive threats. The FTC characterizes Instagram and WhatsApp as elements of a broader anticompetitive acquisition strategy; Meta contests the government's case.

19. Policy Tool 5 – Counterfactual Analysis

A central question is:

What probably would have happened without the acquisition?

This is called the counterfactual.

Authorities may compare:

Merger scenario

Incumbent purchases the emerging competitor.

versus

No-merger scenario

The target:

• remains independent;
• receives additional financing;
• launches its product;
• expands;
• enters adjacent markets;
• develops competing technology; or
• is purchased by another company.

The more uncertain the target's future development, the harder the evidentiary problem becomes.

20. Policy Tool 6 – Innovation-Specific Merger Analysis

Traditional concentration measures may be insufficient in innovation markets.

Authorities can therefore examine:

Innovation spaces

Areas in which several companies are pursuing competing research strategies.

Pipeline products

Products that have not reached commercialization.

R&D capabilities

Research personnel, patents, datasets and technical infrastructure.

Future market positions

Whether one party could become an important competitor.

Dow/DuPont is especially important in demonstrating this broader innovation-centered approach.

21. Policy Tool 7 – Retrospective Merger Review

Another important policy mechanism is studying acquisitions after they have occurred.

The FTC's merger-retrospective program examines completed mergers to understand effects on factors including:

• prices;
• product variety;
• quality;
• innovation;
• consumer welfare;
• efficiency; and
• profitability.

The results can help authorities improve future merger analysis and identify weaknesses in previous enforcement methods.

Retrospective analysis is particularly useful for killer-acquisition policy because authorities can compare predictions made during merger review with actual post-acquisition outcomes.

22. Policy Tool 8 – Remedies

Where an acquisition threatens innovation competition, authorities have several possible responses.

Prohibition

The transaction may be prevented entirely.

Structural remedies

The parties may have to sell:

• a business division;
• technology;
• intellectual property;
• manufacturing assets;
• research facilities; or
• development projects.

Behavioural remedies

Authorities may impose requirements concerning:

• access;
• interoperability;
• licensing;
• non-discrimination; or
• supply conditions.

Divestiture after completion

In exceptional circumstances, authorities may seek to unwind an already completed transaction.

Illumina/GRAIL demonstrates the practical significance of divestiture: after extensive U.S. proceedings, Illumina announced that GRAIL would be divested.

23. Major Evidentiary Problem

Killer-acquisition cases contain a fundamental difficulty:

competition authorities are trying to determine a future that never occurred.

Suppose an incumbent acquires a start-up.

The authority may argue:

Without the acquisition, the start-up could have become an important competitor.

The acquiring company may respond:

The start-up might never have succeeded.

Both propositions concern uncertain future events.

Authorities therefore need evidence such as:

• funding history;
• technological milestones;
• customer adoption;
• market testing;
• business plans;
• investment forecasts;
• patent portfolios;
• internal incumbent assessments;
• third-party investor assessments;
• barriers to entry; and
• evidence concerning alternative competitors.

This evidentiary challenge was particularly visible in FTC v. Meta/Within, where potential-entry theories were central to the litigation.

24. False Positives and False Negatives

Effective policy must manage two opposite risks.

False negative

A harmful acquisition is permitted.

The target subsequently disappears as an independent competitive force, and consumers lose future competition or innovation.

False positive

A beneficial acquisition is prohibited because authorities incorrectly predict competitive harm.

That could reduce investment incentives, prevent useful technological integration or make financing innovative start-ups more difficult.

Consequently, prevention policy generally should not presume that every acquisition of a start-up by an incumbent is harmful.

25. Pharmaceuticals and Biotechnology

The original economic literature on killer acquisitions focused heavily on pharmaceuticals.

The concern is particularly strong because pharmaceutical companies often possess overlapping development pipelines.

For example:

Company A → marketed medicine.

Company B → experimental competing treatment.

A purchases B.

If A subsequently terminates B's research, the transaction might protect A's existing medicine from future competition.

However, termination alone does not establish a competition-law violation. Drug-development projects frequently fail for legitimate reasons involving safety, efficacy, regulatory approval, cost or scientific feasibility.

Competition authorities therefore need to distinguish strategic elimination from ordinary research failure.

26. Digital Markets

Digital killer acquisitions can be even harder to identify because competitive significance may derive from assets other than revenue.

A start-up might possess:

• millions of users;
• unique algorithms;
• valuable datasets;
• strong network effects;
• artificial-intelligence models;
• developer communities;
• complementary technology; or
• rapidly increasing engagement.

An incumbent may therefore acquire an important future rival long before the target becomes profitable.

The Instagram and WhatsApp acquisitions have become prominent reference points in this policy debate, although whether those acquisitions constitute unlawful monopolization remains a matter of litigation rather than something that should simply be assumed.

27. Artificial Intelligence and Future Killer-Acquisition Policy

AI creates additional challenges.

Competitive importance can depend on:

Compute + models + training data + specialized talent + distribution + cloud infrastructure.

A young AI company could have very limited turnover while controlling valuable models, datasets or researchers.

Competition authorities may therefore increasingly need to consider whether transactions eliminate independent competition involving:

• foundation models;
• AI applications;
• specialized datasets;
• semiconductor technology;
• cloud infrastructure;
• AI research teams; or
• distribution channels.

This is one reason merger frameworks increasingly emphasize dynamic and innovation-based competition rather than relying entirely on current market shares.

The European Commission's ongoing review of its merger guidelines explicitly responds to major changes including digitalisation and evolving market realities. Draft revised guidelines were published in April 2026.

28. Comparison of Traditional and Killer-Acquisition Analysis

The essential development is therefore movement from a purely static assessment toward a more dynamic assessment of competitive development.

29. Principles for an Effective Prevention Policy

An effective killer-acquisition framework generally requires a combination of measures rather than a single rule:

1. Broader jurisdictional coverage so strategically significant low-turnover transactions are not automatically invisible.
2. Potential-competition analysis examining credible future entry.
3. Innovation analysis covering R&D pipelines and technological capabilities.
4. Transaction-value and other alternative thresholds where appropriate.
5. Targeted reporting or call-in mechanisms for transactions that escape conventional notification thresholds.
6. Internal-document evidence to understand the commercial rationale and how the parties assessed one another.
7. Counterfactual analysis comparing acquisition and independence scenarios.
8. Proportionate remedies, including prohibition or divestiture where the legal standard for intervention is satisfied.
9. Retrospective studies to test whether previous merger predictions were accurate.
10. Procedural safeguards and evidence requirements so that ordinary acquisitions of innovative businesses are not treated as anticompetitive merely because the purchaser is large.

Conclusion

Killer acquisition prevention policy represents an important evolution from traditional static merger control toward protection of dynamic and innovation-based competition. The central concern is that a powerful incumbent may acquire an emerging competitor before conventional indicators such as revenue and market share reveal the target's true competitive significance.

The major cases illustrate different parts of that problem. FTC v. Meta highlights alleged elimination of nascent digital threats; Illumina/GRAIL demonstrates both innovation concerns and the jurisdictional difficulties created by low-turnover targets; Meta/Within illustrates the evidentiary limits of potential-entry theories; Adobe/Figma demonstrates concern with future and reverse killer acquisitions; Dow/DuPont shows the importance of protecting R&D competition; and Roche/Spark demonstrates why an innovative acquisition should not automatically be presumed harmful. Nvidia/Arm provides a further example of preventive intervention where control of strategically important technology could affect rivals.

The policy challenge is therefore to identify acquisitions that genuinely threaten future competitive independence without discouraging acquisitions that legitimately finance innovation, combine complementary technologies or enable successful commercialization. Modern competition policy addresses that challenge through expanded notification mechanisms, potential-competition theories, innovation analysis, counterfactual evidence, retrospective review and, where legally justified, structural remedies.